Last reviewed · How we verify

DFD-03 — Competitive Intelligence Brief

DFD-03 (DFD-03) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective Androgen Receptor Modulator (SARM). Area: Endocrinology / Musculoskeletal.

phase 3 Selective Androgen Receptor Modulator (SARM) Androgen Receptor (AR) Endocrinology / Musculoskeletal Small molecule Live · refreshed every 30 min

Target snapshot

DFD-03 (DFD-03) — Dr. Reddy's Laboratories Limited. DFD-03 is a selective androgen receptor modulator (SARM) that binds to androgen receptors to promote anabolic effects while minimizing androgenic side effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DFD-03 TARGET DFD-03 Dr. Reddy's Laboratories Limited phase 3 Selective Androgen Receptor Modulator (SARM) Androgen Receptor (AR)
SAR231893 SAR231893 Sanofi marketed Selective androgen receptor modulator (SARM) Androgen receptor (AR)
ASC-01 ASC-01 Otsuka Pharmaceutical Co., Ltd. phase 3 Selective androgen receptor modulator (SARM) Androgen receptor (AR)
AGN-199201 AGN-199201 Allergan phase 3 Selective androgen receptor modulator (SARM) Androgen receptor (AR)
DWJ1319 DWJ1319 Daewoong Pharmaceutical Co. LTD. phase 3 Selective Androgen Receptor Modulator (SARM) Androgen Receptor (AR)
"Raylis" "Raylis" The Clinic of Men's Health and Couple Longevity, Russia phase 3 Selective androgen receptor modulator (SARM) Androgen receptor
AGN-151586 AGN-151586 AbbVie phase 3 Selective Androgen Receptor Modulator (SARM) Androgen Receptor (AR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective Androgen Receptor Modulator (SARM) class)

  1. AbbVie · 1 drug in this class
  2. Astellas Pharma Inc · 1 drug in this class
  3. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class
  4. Dr. Reddy's Laboratories Limited · 1 drug in this class
  5. Hanmi Pharmaceutical Company Limited · 1 drug in this class
  6. Merck Sharp & Dohme LLC · 1 drug in this class
  7. Tanabe Pharma Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DFD-03 — Competitive Intelligence Brief. https://druglandscape.com/ci/dfd-03. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: